Rx Promotional Campaign Based On Individual Symptoms Gives FDA Allergic Reaction
This article was originally published in The Pink Sheet Daily
Executive Summary
Meda’s allergic rhinitis drug Astepro (azelastine) draws an FDA letter for a telephone sales script that focused on the drug’s effect on nasal congestion, which was not studied separately from its effect on other symptoms.